文献速递神经肿瘤

hnRNPA1的高分子量亚型赋予U87MG与LN229胶质瘤细胞对替莫唑胺的耐药性

Higher isoform of hnRNPA1 confer Temozolomide resistance in U87MG & LN229 glioma cells.
PubMed 文献 · J Neurooncol · 2024-11-25

本研究在两种不表达MGMT的胶质瘤细胞系U87MG与LN229中诱导替莫唑胺耐药,发现耐药细胞中剪接因子SF2/ASF1与hnRNPA1高分子量亚型Var2表达增加;敲低SF2/ASF1可使Var2回复为Var1,敲低Var2可促进凋亡,并在Wortmannin处理下增强,结论为靶向hnRNPA1 Var2可诱导化疗增敏。

要点

  • U87MG与LN229耐药细胞中hnRNPA1高分子量亚型Var2表达增多。
  • 敲低SF2/ASF1使U87MG耐药细胞中hnRNPA1 Var2回复为Var1。
  • 敲低hnRNPA1 Var2促进耐药细胞凋亡,Wortmannin处理可进一步增强。

核心结论

  • 靶向hnRNPA1高分子量亚型Var2可特异性诱导表达MGMT的替莫唑胺耐药U87MG细胞及不表达MGMT的替莫唑胺耐药LN229细胞发生化疗增敏。

研究设计与样本

  • 研究使用两种不表达O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)的胶质瘤细胞系U87MG与LN229。
  • U87MG细胞在替莫唑胺浓度从50μM递增至400μM中培养,LN229细胞培养至200μM,直至两种细胞获得替莫唑胺耐药。
  • 两种细胞均持续维持在其最高替莫唑胺剂量中培养。
  • 采用特异性siRNA转染方法将剪接因子蛋白SF2/ASF1与替莫唑胺耐药细胞中hnRNPA1蛋白丰度进行功能关联。

主要发现

  • U87MG替莫唑胺耐药后,前mRNA剪接因子SF2/ASF1、异质性核糖核蛋白A1(hnRNPA1)及MGMT蛋白表达增加。
  • LN229替莫唑胺耐药细胞中未观察到MGMT表达。
  • hnRNPA1 mRNA测序证实耐药细胞中其高分子量亚型独家丰度增高,同时SF2/ASF1表达增加。
  • 使用特异性siRNA敲低SF2/ASF1后,U87替莫唑胺耐药细胞中hnRNPA1高分子量亚型Var2回复为低分子量亚型hnRNPA1 Var1,表明hnRNPA1高分子量亚型丰度依赖于SF2/ASF1剪接因子。
  • 在替莫唑胺耐药U87MG与LN229细胞中选择性敲低hnRNPA1高分子量亚型Var2可促进凋亡,Wortmannin(PI3激酶抑制剂)处理进一步特异性增强该凋亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gliblastoma is a malignant brain tumor; despite available treatment modalities, the tumor reoccurrence rate persist in the currently prescribed Temozolomide chemotherapy. Study aimed to study the inquisitive role of RNA binding splice factor protein hnRNPA1 in promoting glioma resistance against Temozolomide drug and therapeutic insights. METHODS: In this study two non-expressing O6-methylguanine-DNA methyltransferase (MGMT) glioma cell lines U87MG & LN229. U87MG cells were grown in Temozolomide from 50μM upto 400μM & LN229 cells grown upto 200μM, till then both these cells acquired Temozolomide resistance. Both of these cells were grown & maintained continously in its highest dose of Temozolomide (TMZ). Splice factor protein SF2/ASF1 was functionally correlated with abundance of hnRNPA1 protein in Temozolomide (TMZ) resistant cells using its specific siRNA transfection approach, in detrmining SF2/ASF1 mediated hnRNPA1 splicing and Temozolomide resistant reversal. RESULTS: U87MG TMZ resistance, results an increase in the expression of pre mRNA-splicing factor SF2/ASF1, Heterogeneous Ribonucleoprotein A1 (hnRNPA1) and O6-methylguanine-DNA methyltransferase (MGMT) protein. MGMT expression was not observed in LN229 TMZ resistant cells. Further, mRNA sequencing of hnRNPA1 confirmed the exclusive abundance of its higher isoform in TMZ- resistant cells along with increase in SF2/ASF1 expression. Knocking down of SF2/ASF1 using its specific siRNA reverted the higher isoform of hnRNPA1 isoform Var2 to its lower isoform hnRNPA1 Var1 in U87 TMZ resistant cells, reveals hnRNPA1 alternative higher isoform abundance is SF2/ASF1 splice factor dependent. Additionally, selective knock down of hnRNPA1 higher isoform Var2 in TMZ resistant U87MG & LN229 promotes apoptosis, was further specfically enhanced on Wortmannin (PI3Kinase inhibitor) treatment. CONCLUSION: Targeting higher isoform Var2 of hnRNPA1 specifically induces chemosensitization in MGMT expressed Temozolomide resistant U87MG as well as in MGMT non-expressed LN229 TMZ resistant cells.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Bhardwaj S, Sanjay, Yadav AK, et al. Higher isoform of hnRNPA1 confer Temozolomide resistance in U87MG & LN229 glioma cells. J Neurooncol. 2024. PMID: 39585598. doi:10.1007/s11060-024-04831-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。